US-based biopharmaceutical services provider Parexel International has designated Rutgers New Jersey Medical School (NJMS) in Newark as a Key Alliance Site for hosting clinical trials from Parexel’s client base.

Under the agreement, Parexel will have the opportunity to place early- to late-phase studies at NJMS, which on 1 July became part of the newly created Rutgers Biomedical and Health Sciences unit within Rutgers, the state university of New Jersey.

The School has a clinical research centre unit, which conducts studies across a broad variety of medical specialties.

The arrangement will also give Parexel access to experienced investigators to help design clinical trials and to information resources through the NJMS electronic medical record system.

These integrated resources will enable Parexel and NJMS to plan, develop and execute clinical trial studies with shorter timelines, the School said.

Leading treatments

“With Parexel, NJMS looks forward to further developing our academic enterprise and biomedical research presence, as well as increasing patient recruitment and referrals,” commented William Gause, senior associate dean for research at NJMS.

“Most important, the long-term agreement will allow us to continue offering leading treatments and new medicines to patients in Newark and the rest of Essex County.”

Clinical trials hosted at the NJMS clinical research center unit will assess medicines and other products for a wide range of conditions, including cancer, obesity and diabetes as well as cardiovascular, respiratory and infectious diseases.

Many of these studies will be conducted in collaboration with University Hospital, New Jersey Medical School’s flagship teaching hospital.